Authorities should reconsider whether herbal medicines, as conventional drugs, need regulation and should be tested for safety, tolerabilityandefficacy for the benefit of our patients.
The day before the opening today of the ASH conference in Atlanta, TG Therapeitics announced it has initiated a phase 1 and 2 clinical trials to evaluate the safety, tolerabilityandefficacy of its product, TG-1101, a novel third-generation anti-CD20 monoclonal antibody, in combination with Revilimid for patients with relapsed or refractory B-cell lymphoid malignancies who were previously treated with anti-CD20 antibody therapy.